Whole genome sequencing solution
ResolveDNA™, powered by PTA, provides superior whole genome amplification (WGA) performance metrics in single cells compared to all current methods
BioSkryb has ushered in a whole new era of single-cell whole genome amplification. The benefits of the BioSkryb ResolveDNA™ technology include the ability to control the amplicon size during amplification. This allows the incorporation of barcode identifiers into each sample template, enabling unparalleled reproducibility and sensitive detection of DNA lesions.
Primary Template-directed Amplification (PTA) is a novel, more accurate, whole genome amplification (WGA) approach for single cells or ultra-low DNA input samples. The PTA platform elevates single cell genome variant calling metrics to a new gold standard compared to current methodologies.
BioSkryb’s complete workflow solution is especially useful in cancer research as it allows the detection of single resistant mutant cells (MRD) in heterogeneous cancers such as leukemia. It also enables new applications for gene sequencing that need a level of resolution simply not available today.
Tops News & Media Coverage
BioSkryb Genomics and Cooper Surgical Ink Multi-Year Deal to Accelerate Clinical Discovery and Diagnostics in Women’s Reproductive Health
BioXpedia A/S and BioSkryb Genomics Announce European Partnership to Provide Groundbreaking, Single-Cell, Multiomic Analysis for Novel Target Identification and Therapeutic Development
BioSkryb Genomics Launches ResolveOME Early Access Program for Full Genome and Transcriptome Amplification From a Single Cell, in Conjunction With Its Innovative Bioinformatics Platform, BaseJumper™
BioSkryb Genomics and ALS Automated Lab Solutions GmbH Sign U.S. Distribution Agreement to Power Unprecedented Single Cell Spatial Genomics
BioSkryb Completes Move into New Global Headquarters in Durham, N.C.
BioSkryb Appoints Gary Harton, Ph.D., Chief Scientific Officer